• 검색 결과가 없습니다.

[PDF] Top 20 Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.

Has 10000 "Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance." found on our website. Below are the top 20 most common "Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.".

Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.

Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.

... ng therapy , genotypi c anal ysi s of rtM204 sequences,and LAM was swi tched to ADV ...ADV refractory i f they had al i mi ted vi rol ogi cal response wi th or wi thout documented ADV mutati ons whi ... See full document

30

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

... ADV, adefovir dipivoxil; CHB, chronic hepatitis B; CVR, complete virologic response; ETV, entecavir; FTC, emtricitabine; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LAM, ... See full document

3

Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies

Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies

... term efficacy of ADV-based combination therapies, ...CHB patients with genotypic resistance to ...rates of virological response in patients treated with ... See full document

10

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients

... tion of patients with cirrhosis and mean age, were different between the 2 ...occurrence of HCC. Second, bone mineral density was not evaluated in the patients who participated ... See full document

12

Efficacy of entecavir verses lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with allogeneic stem cell transplant

Efficacy of entecavir verses lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with allogeneic stem cell transplant

... Sixty patients, thirty in each group who received LVD or ETV prophylaxis were included in the ...duration of prophylaxis of each drugs and clinical and virological follow up post ... See full document

1

Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization

Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization

... found in 56 of the 60 samples ...results of the two assays, as presented in Figure 2. In all of these cases, RFMP indicated the presence of additional virus species (Table ... See full document

9

Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine resistant chronic hepatitis B patients

Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine resistant chronic hepatitis B patients

... HBeAg 양성인 환자가 64명(84. 2%)이었고 간경변이 동반된 환자가 20명(26. 3%) 이었다. B.연구 방법 혈청학적 검사는 HBeAg,anti -HBe,ALT,AST,HBV DNA를 아데포비 어 투여 직전과 투여 중 3개월 간격으로 측정하였다.또한 투여 전 YMDD 변이 와 precore 변이(G1896A)존재 여부를 측정하였고,아데포비어 내성 돌연변이 ... See full document

29

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

... combination therapy showed high rates of RVR, ETR, and SVR12 when used to treat patients with chronic HCV genotype 1b infec- tion in real ...combination therapy showed ... See full document

8

Changes in serum histologic surrogate markers and procollagen III N- terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy

Changes in serum histologic surrogate markers and procollagen III N- terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy

... risk of complications, patient discomfort, and inter-observer variation (Poynard et al, 2000; Regev et al, 2002; Bedossa et al, ...usefulness of a liver biopsy as the follow-up method for patients ... See full document

35

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B

... performance of the HepB Typer-Entecavir kit under a variety of analytical ...limit of the HepB Typer-Entecavir kit was found to be as low as 500 ...Presence of anticoagulants, ... See full document

10

Association between single nucleotide polymorphisms in deoxycytidine kinase and lamivudine monotherapy response among patients with chronic hepatitis B

Association between single nucleotide polymorphisms in deoxycytidine kinase and lamivudine monotherapy response among patients with chronic hepatitis B

... implicated in drug ...inhibitor of polymerase. 15-18 One or more steps in sequential phosphorylation of NRTIs from initial monophosphate to diphosphate to triphosphate formation can be rate ... See full document

67

Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis

Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis

... definitions in various clinical settings, because pattern of prescribing antiviral agent might be quite different depending on the clinical ...133 patients were not enough to validate for 7166 ... See full document

13

Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients

Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients

... number of cases in the TDF group was relatively small because TDF has been used only since 2013 in our ...[3], with a long-term follow-up duration (mean ...dysfunction of nucleotide ... See full document

8

Long-term efficacy of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea

Long-term efficacy of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea

... Long-term efficacy of combination therapy with Interferon alpha and ribavirin for chronic hepatitis C in Korea.. Jie Hyun Kim.[r] ... See full document

47

Peginterferon alpha and ribavirin combination therapy in
patients with hepatitis C virus-related liver cirrhosis

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

... cirrhotic patients, the SVR rate of the genotype non-1 group was similar at around ...SVRs of genotype 1 group was reported to be very low at 13-14%, 14,15 however, the SVR was relatively high ... See full document

6

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

... Most patients in this study were treatment-naive and HCV mono-infected; caution when ex- trapolating these findings to other patients groups, such as those previously treated for HCV infection or ... See full document

8

were  treated  with  lamivudine.  The  duration  of  lamivudine  therapy  was  from  6  to  64  months  (mean  20  months).

were treated with lamivudine. The duration of lamivudine therapy was from 6 to 64 months (mean 20 months).

... The Korean Journal of Gastroenterology: Vol. 42, No. 4, 2003 310 HBeAg의 음전이나 혈청전환으로 하여도 재발률에 차이가 없어 치료 종료 시점으로 할 수 없으며 추후 다른 인자나 다른 방법을 통해 종료 시점을 찾는 노력이 필요하겠다. 치 료 반응 후 치료를 중단한 환자에서 라미부딘 총 사용 기간 이 12개월 미만 투여군과 ... See full document

10

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients

... 것을 목표로 하였다. 방법: 대상환자는 총 45명으로, NUC 치료시작후 HBV DNA가 음성화되고, 최소 18개월 간 음성이 지속되어 NUC treatment를 중단한 E항원음성 만성간염 환자를 대상으로 하 였고, NUC의 종류는 각각 entecavir 25명, lamivudine 14명, adefovir 6명이었습니다. ... See full document

23

The efficacy of laparoscopic cholecystectomy without discontinuation in patients on antithrombotic therapy

The efficacy of laparoscopic cholecystectomy without discontinuation in patients on antithrombotic therapy

... Antiplatelet therapy is known to be the most effective treatment that can prevent primary and secondary cardiovas- cular events up to ...risk patients of po- tential cardiovascular or cerebrovascular ... See full document

6

We report three cases of low dose adefovir-induced hypophosphatemic osteomalacia with fractures

We report three cases of low dose adefovir-induced hypophosphatemic osteomalacia with fractures

... agent in the treatment of chronic hepatitis B virus ...for patients infected with lamivudine-refractory hepatitis ...studies of low-dose ... See full document

8

Show all 10000 documents...